Time to end secret data laboratories—starting with the CDC
The American people are waking up to the fact that too many public health leaders have not always been straight with them. Despite housing treasure…
Thought Leader: Marty Makary
Joe Grogan: The biotech industry needs to make its case for bold change to the White House
It can’t get what it wants unless it asks
On April 15, President Trump issued an awaited executive order on drug pricing, kicking off a new frenzy among lobbyists and consultants. That frenzy has gone into overdrive with the latest proposal from the White House to examine cuts to Medicaid drug reimbursement, slashing prices to extortionate levels foreign governments demand.
Unlike Trump’s first term, the pharmaceutical industry is in far more peril than it has ever been in, and the biotech industry needs to ask itself an important question: Where does it fit in Trump’s vision for a new American Golden Age?
The opportunity is there to lay out a compelling case that biotech should sit beside space commercialization, energy production, and technology as partners in Trump’s grand ambitions. If biotech misses the moment, it will be just another industry staggering about the rubble of decaying factories, wondering how it lost out to China.
This article is written by WWSG exclusive thought leader, Joseph Grogan. Read the full article here.
Looking for a speaker who understands the intersection of healthcare, policy, and innovation? Joe Grogan, former White House Domestic Policy Council Director, brings unparalleled insights into U.S. healthcare reform, regulatory strategy, and the future of American healthcare. With his firsthand experience shaping national health policy, Grogan delivers compelling, actionable perspectives for organizations navigating today’s complex healthcare landscape. Book him for your next event, contact us!
Relevant posts
Newt Gingrich | Election 2024 – State of the Race
Newt Gingrich discusses the upcoming election with two experienced pollsters, John McLaughlin and Doug Sosnik. They discuss key issues voters are considering, the six or…
Jay Clayton on taxing unrealized gains, price gouging ban proposals
Former SEC Chair Jay Clayton joins ‘Squawk Box’ to discuss the Trump vs. Harris economic agendas, taxing unrealized capital gains, federal price gouging ban, and…
More with this speaker
Joe Grogan: Is cheaper better if it kills cancer cures?
Thought Leader: Joseph Grogan
Joe Grogan: The Alzheimer’s Economic Threat
Thought Leader: Joseph Grogan